Zacks Investment Research downgraded shares of AIT Therapeutics (OTCMKTS:AITB) from a buy rating to a hold rating in a research report sent to investors on Wednesday, January 3rd.
According to Zacks, “AIT Therapeutics, Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. It is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria. AIT Therapeutics, Inc. is based in Ness Ziona, Israel. “
Separately, Roth Capital reissued a buy rating on shares of AIT Therapeutics in a report on Monday, September 25th.
AIT Therapeutics (OTCMKTS:AITB) last issued its earnings results on Friday, November 3rd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.59). analysts anticipate that AIT Therapeutics will post -3.22 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/01/20/ait-therapeutics-aitb-stock-rating-lowered-by-zacks-investment-research.html.
AIT Therapeutics Company Profile
AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.